Testing devices or experimental systems? Cancer clinical trials take the genomic turn
- 1 June 2014
- journal article
- research article
- Published by Elsevier in Social Science & Medicine
- Vol. 111, 74-83
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes for Health Research (MOP-93553)
- the Fonds Québécois de la Recherche sur la Société et la Culture (SE-124896, SE-164195)
- Social Sciences and Humanities Research Council of Canada (410-2011-2290)
This publication has 25 references indexed in Scilit:
- Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to ProgressClinical Cancer Research, 2014
- Biopsies: next-generation biospecimens for tailoring therapyNature Reviews Clinical Oncology, 2013
- Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and TreatmentJournal of Clinical Oncology, 2013
- Identifying ontologies in a clinical trialSocial Studies of Science, 2013
- The Pharmacology of Distributed Experiment – User-generated Drug InnovationBody & Society, 2012
- Adaptive clinical trials in oncologyNature Reviews Clinical Oncology, 2011
- Reengineering Translational Science: The Time Is RightScience Translational Medicine, 2011
- The clinical trials system is brokenNature Clinical Practice Oncology, 2008
- The Growing Engagement of Emergent Concerned Groups in Political and Economic LifeScience, Technology, & Human Values, 2007
- The MINDACT trial: The first prospective clinical validation of a genomic toolMolecular Oncology, 2007